Armistice Capital, LLC Chinook Therapeutics, Inc. Transaction History

Armistice Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$12.59 - $18.8 $9.52 Million - $14.2 Million	-756,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$12.02 - $16.69 $3.37 Million - $4.67 Million	-280,000 Reduced 27.03%	756,000 $12.4 Million
Q4 2021 Feb 14, 2022	SELL	$10.69 - $16.83 $2.01 Million - $3.16 Million	-188,000 Reduced 15.36%	1,036,000 $16.9 Million
Q3 2021 Nov 15, 2021	SELL	$11.5 - $14.86 $138,000 - $178,320	-12,000 Reduced 0.97%	1,224,000 $15.6 Million
Q2 2021 Aug 16, 2021	BUY	$13.6 - $18.98 $16.8 Million - $23.5 Million	1,236,000 New	1,236,000 $17.5 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Armistice Capital, LLC with notifications on news.